Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 147

1.

Restoration of chemosensitivity for doxorubicin and cisplatin in chondrosarcoma in vitro: BCL-2 family members cause chemoresistance.

van Oosterwijk JG, Herpers B, Meijer D, Briaire-de Bruijn IH, Cleton-Jansen AM, Gelderblom H, van de Water B, Bovée JV.

Ann Oncol. 2012 Jun;23(6):1617-26. doi: 10.1093/annonc/mdr512. Epub 2011 Nov 23.

PMID:
22112972
2.

Platinum compounds sensitize ovarian carcinoma cells to ABT-737 by modulation of the Mcl-1/Noxa axis.

Simonin K, N'Diaye M, Lheureux S, Loussouarn C, Dutoit S, Briand M, Giffard F, Brotin E, Blanc-Fournier C, Poulain L.

Apoptosis. 2013 Apr;18(4):492-508. doi: 10.1007/s10495-012-0799-x.

PMID:
23344663
3.

Inhibition of Bcl-2 and Bcl-X enhances chemotherapy sensitivity in hepatoblastoma cells.

Lieber J, Kirchner B, Eicher C, Warmann SW, Seitz G, Fuchs J, Armeanu-Ebinger S.

Pediatr Blood Cancer. 2010 Dec 1;55(6):1089-95. doi: 10.1002/pbc.22740.

PMID:
20680965
4.

Inhibition of Bcl-2 family members sensitises soft tissue leiomyosarcomas to chemotherapy.

de Graaff MA, de Rooij MA, van den Akker BE, Gelderblom H, Chibon F, Coindre JM, Marino-Enriquez A, Fletcher JA, Cleton-Jansen AM, Bovée JV.

Br J Cancer. 2016 May 24;114(11):1219-26. doi: 10.1038/bjc.2016.117. Epub 2016 May 3.

5.

[Bcl-2 inhibitor ABT-737 enhances the cisplatin-induced apoptosis in breast cancer T47D cells].

Chen ZJ, Zhang B, Pan SH, Zhao HM, Zhang Y, Feng WH, Li YY, Cao XC.

Zhonghua Zhong Liu Za Zhi. 2011 Dec;33(12):891-5. Chinese.

PMID:
22340096
6.

ABT-737 synergizes with chemotherapy to kill head and neck squamous cell carcinoma cells via a Noxa-mediated pathway.

Li R, Zang Y, Li C, Patel NS, Grandis JR, Johnson DE.

Mol Pharmacol. 2009 May;75(5):1231-9. doi: 10.1124/mol.108.052969. Epub 2009 Feb 25.

7.

TTFields alone and in combination with chemotherapeutic agents effectively reduce the viability of MDR cell sub-lines that over-express ABC transporters.

Schneiderman RS, Shmueli E, Kirson ED, Palti Y.

BMC Cancer. 2010 May 23;10:229. doi: 10.1186/1471-2407-10-229.

8.

Targeting BCL-2 family proteins to overcome drug resistance in non-small cell lung cancer.

Wesarg E, Hoffarth S, Wiewrodt R, Kröll M, Biesterfeld S, Huber C, Schuler M.

Int J Cancer. 2007 Dec 1;121(11):2387-94.

9.

Inhibition of P-glycoprotein functionality by vandetanib may reverse cancer cell resistance to doxorubicin.

Jovelet C, Bénard J, Forestier F, Farinotti R, Bidart JM, Gil S.

Eur J Pharm Sci. 2012 Aug 15;46(5):484-91. doi: 10.1016/j.ejps.2012.03.012. Epub 2012 Mar 30.

PMID:
22484209
10.

Alterations in the Noxa/Mcl-1 axis determine sensitivity of small cell lung cancer to the BH3 mimetic ABT-737.

Hauck P, Chao BH, Litz J, Krystal GW.

Mol Cancer Ther. 2009 Apr;8(4):883-92. doi: 10.1158/1535-7163.MCT-08-1118.

11.

Co-targeting of Bcl-2 and mTOR pathway triggers synergistic apoptosis in BH3 mimetics resistant acute lymphoblastic leukemia.

Iacovelli S, Ricciardi MR, Allegretti M, Mirabilii S, Licchetta R, Bergamo P, Rinaldo C, Zeuner A, Foà R, Milella M, McCubrey JA, Martelli AM, Tafuri A.

Oncotarget. 2015 Oct 13;6(31):32089-103. doi: 10.18632/oncotarget.5156.

12.

'Seed' analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-XL inhibitor ABT-737.

Lin X, Morgan-Lappe S, Huang X, Li L, Zakula DM, Vernetti LA, Fesik SW, Shen Y.

Oncogene. 2007 Jun 7;26(27):3972-9. Epub 2006 Dec 18.

PMID:
17173063
13.

Inhibition of Bcl-xL by ABT-737 enhances chemotherapy sensitivity in neurofibromatosis type 1-associated malignant peripheral nerve sheath tumor cells.

Lee SJ, Park HJ, Kim YH, Kim BY, Jin HS, Kim HJ, Han JH, Yim H, Jeong SY.

Int J Mol Med. 2012 Aug;30(2):443-50. doi: 10.3892/ijmm.2012.1013. Epub 2012 May 29.

PMID:
22664653
14.

BH3 mimetic ABT-737 and a proteasome inhibitor synergistically kill melanomas through Noxa-dependent apoptosis.

Miller LA, Goldstein NB, Johannes WU, Walton CH, Fujita M, Norris DA, Shellman YG.

J Invest Dermatol. 2009 Apr;129(4):964-71. doi: 10.1038/jid.2008.327. Epub 2008 Nov 6.

15.

siRNA-based targeting of antiapoptotic genes can reverse chemoresistance in P-glycoprotein expressing chondrosarcoma cells.

Kim DW, Kim KO, Shin MJ, Ha JH, Seo SW, Yang J, Lee FY.

Mol Cancer. 2009 May 15;8:28. doi: 10.1186/1476-4598-8-28.

16.

Discovery of marinopyrrole A (maritoclax) as a selective Mcl-1 antagonist that overcomes ABT-737 resistance by binding to and targeting Mcl-1 for proteasomal degradation.

Doi K, Li R, Sung SS, Wu H, Liu Y, Manieri W, Krishnegowda G, Awwad A, Dewey A, Liu X, Amin S, Cheng C, Qin Y, Schonbrunn E, Daughdrill G, Loughran TP Jr, Sebti S, Wang HG.

J Biol Chem. 2012 Mar 23;287(13):10224-35. doi: 10.1074/jbc.M111.334532. Epub 2012 Feb 6.

17.

Interleukin 6 augments lung cancer chemotherapeutic resistance via ataxia-telangiectasia mutated/NF-kappaB pathway activation.

Yan HQ, Huang XB, Ke SZ, Jiang YN, Zhang YH, Wang YN, Li J, Gao FG.

Cancer Sci. 2014 Sep;105(9):1220-7. doi: 10.1111/cas.12478. Epub 2014 Sep 8.

18.

RNA interference screening identifies a novel role for autocrine fibroblast growth factor signaling in neuroblastoma chemoresistance.

Salm F, Cwiek P, Ghosal A, Lucia Buccarello A, Largey F, Wotzkow C, Höland K, Styp-Rekowska B, Djonov V, Zlobec I, Bodmer N, Gross N, Westermann F, Schäfer SC, Arcaro A.

Oncogene. 2013 Aug 22;32(34):3944-53. doi: 10.1038/onc.2012.416. Epub 2012 Oct 1.

PMID:
23027129
19.

BH3 mimetics to improve cancer therapy; mechanisms and examples.

Zhang L, Ming L, Yu J.

Drug Resist Updat. 2007 Dec;10(6):207-17. Epub 2007 Oct 24. Review.

20.

YM-155 potentiates the effect of ABT-737 in malignant human glioma cells via survivin and Mcl-1 downregulation in an EGFR-dependent context.

Jane EP, Premkumar DR, DiDomenico JD, Hu B, Cheng SY, Pollack IF.

Mol Cancer Ther. 2013 Mar;12(3):326-38. doi: 10.1158/1535-7163.MCT-12-0901. Epub 2013 Jan 16.

Supplemental Content

Support Center